Interpretation of China’s Pharmaceutical Patent Term Compensation (PTE) System
From patent application to final approval and marketing, a new drug often takes more than ten years. During this period, the time spent on clinical trials
News
- Welcome to MeritsIP Website -
- Home -News
China’s innovative drug exports accelerate again—this year, overseas licensing exceeded $120 billion
On September 14, the launch ceremony of the 2026 “National Drug Safety Publicity Week” was held in Beijing. Huang Guo, Secretary of the Party Leadership Group
Key points for drafting drug formulation patents
Drug formulation patents are a key link connecting APIs with clinical applications. A compound patent may protect the structure of a molecule, but whether a molecule
Intellectual Property Newsletter by MeritsIP, September 14, 2026
# China Launches 2026 National Patent Priority Examination Program to Accelerate High-Value IP Commercialization # China's National Intellectual Property Administration Unveils 2026-Oriented Patent Examination Quality &
Key points in patent layout for small nucleotide drugs (siRNA).
siRNA drugs have become one of the fastest-growing innovative therapies in the biopharmaceutical field in recent years. The biggest difference between them and traditional drugs is:
Co-Co, NewCo, and Early Overseas Expansion: Three New Paths for Chinese Innovative Drugs Going Global
Opening Introduction: In the first half of 2026, the total overseas licensing transaction volume of China’s innovative drugs will exceed $110 billion, accounting for 80% of
Intellectual Property Newsletter by MeritsIP, September 07, 2026
# China's Recent IP Law Enforcement and Judicial Updates: Key Progress in Cross-Border Protection, Digital IP and Right Remedy # UK IPO Updates 2024 Examination Guidelines
From Purinergic Inflammation Biology to an Oral IBD Medicine: The Global P2Y14 Receptor Antagonist Landscape
Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to Global Innovation Asset Watch, a MeritsIP publication examining how emerging life science programs can translate into
From Dual Targeting to Multi-Mechanism Tumor Control: The Global Bispecific and Dual-Payload ADC Landscape
Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to Global Innovation Asset Watch, a MeritsIP publication examining how emerging life science programs can translate into
From Reactive Toxicity Management to Built-In Cytokine Control: The Global Safety-Engineered CD19 CAR-T Landscape
Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to Global Innovation Asset Watch, a MeritsIP publication examining how emerging life science programs can translate into